Novavax (MEX:NVAX) Cyclically Adjusted FCF per Share: MXN-123.97 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVAX Novavax Inc MEX:NVAX
46 GF Score
Price MXN183.13
GF Value MXN53.53
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novavax Cyclically Adjusted FCF per Share?

Novavax MEX:NVAX +8.17% 46 Cyclically Adjusted FCF per Share is MXN-123.97 as of Jun. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 46/100 and a GF Value™ of MXN53.53 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novavax's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN-7.724. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-123.97 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 1.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novavax was 16.70% per year. The lowest was -10.20% per year. And the median was -0.20% per year.

As of today (2026-09-22), Novavax's current stock price is MXN183.13. Novavax's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN-123.97. Novavax's Cyclically Adjusted Price-to-FCF of today is .


Novavax  (MEX:NVAX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novavax Cyclically Adjusted FCF per Share Related Terms


Novavax Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Novavax's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cyclically Adjusted FCF per Share Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -135.48 -151.39 -160.00 -153.89 -142.83

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -155.95 -149.59 -145.48 -134.41 -123.97

MEX:NVAX vs MAZE, SLBT, AVLN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Novavax's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted Price-to-FCF falls into.


MEX:NVAX
46GF Score
Novavax Inc MEX:NVAX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-7.724/333.9520*333.9520
=-7.724

Current CPI (Jun. 2026) = 333.9520.

Novavax Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -102.632 241.428 -141.964
201612 -108.987 241.432 -150.752
201703 -67.503 243.801 -92.464
201706 -12.214 244.955 -16.652
201709 -51.760 246.819 -70.033
201712 -50.833 246.524 -68.861
201803 -73.623 249.554 -98.522
201806 -43.958 251.989 -58.256
201809 -31.310 252.439 -41.420
201812 -53.547 251.233 -71.177
201903 -48.293 254.202 -63.444
201906 -24.680 256.143 -32.177
201909 -27.079 256.759 -35.220
201912 -15.710 256.974 -20.416
202003 -10.484 258.115 -13.564
202006 43.220 257.797 55.987
202009 -7.228 260.280 -9.274
202012 -55.080 260.474 -70.618
202103 180.979 264.877 228.175
202106 31.996 271.696 39.328
202109 -41.282 274.310 -50.258
202112 -92.418 278.802 -110.699
202203 -26.762 287.504 -31.086
202206 -49.549 296.311 -55.843
202209 -17.120 296.808 -19.262
202212 -32.206 296.797 -36.238
202303 -75.571 301.836 -83.612
202306 -27.217 305.109 -29.790
202309 -6.304 307.789 -6.840
202312 -28.720 306.746 -31.267
202403 -10.983 312.332 -11.743
202406 32.237 314.175 34.266
202409 -14.961 315.301 -15.846
202412 -21.414 315.605 -22.659
202503 -21.498 319.799 -22.449
202506 -13.169 322.561 -13.634
202509 13.871 324.800 14.262
202512 -4.187 324.054 -4.315
202603 -3.624 330.213 -3.665
202606 -7.724 333.952 -7.724

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-123.97 mean?
Novavax (MEX:NVAX) has a Cyclically Adjusted FCF per Share of MXN-123.97 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's Cyclically Adjusted FCF per Share too high?
Novavax's current Cyclically Adjusted FCF per Share is MXN-123.97. Overall, Novavax has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Cyclically Adjusted FCF per Share compare to MAZE and SLBT?
Novavax's Cyclically Adjusted FCF per Share of MXN-123.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current Cyclically Adjusted FCF per Share is MXN-123.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN53.53, compared to a current price of MXN183.13 — trading 242.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-123.97. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Cyclically Adjusted FCF per Share is MXN-123.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN183.13 is trading 242.1% above its estimated GF Value™ of MXN53.53. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Cyclically Adjusted FCF per Share: MXN-123.97
  • GF Value™: MXN53.53 vs. price of MXN183.13 (242.1% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc. is a commercial-stage biotechnology company that develops and commercializes vaccines for infectious diseases. Its flagship product, NVX-CoV2373 (Nuvaxovid), is a protein-based COVID-19 vaccine adjuvanted with Matrix-M, its proprietary saponin-based adjuvant technology. The company also develops vaccine candidates targeting influenza, COVID-19/influenza combination, and other infectious diseases, and has pursued programs against respiratory syncytial virus and other pathogens. Novavax sells its COVID-19 vaccine in the United States and internationally, including through partnerships and advance purchase agreements with governments and organizations such as Gavi and the Serum Institute of India, which manufactures and distributes the vaccine in certain markets. Revenue derives primarily from product sales and licensing, royalty, and collaboration agreements. The company operates as a single reportable segment and is headquartered in Gaithersburg, Maryland.
46GF Score

Get the complete analysis for MEX:NVAX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN183.13
Price
MXN53.53
GF Value